GTx, Inc. Provides Corporate Update and Second Quarter 2013 Financial Results

Published: Jul 19, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

GTx, Inc. (Nasdaq: GTXI) today provides a Company update and reports financial results for the second quarter of 2013.

Clinical updates

GTx is evaluating enobosarm (GTx-024) 3 mg, an oral selective androgen receptor modulator, for the prevention and treatment of muscle wasting in patients with advanced non-small cell lung cancer in two pivotal Phase 3 clinical trials.

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Back to news